Janux Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Janux Therapeutics, Inc. on June 26, 2024. The record date for the meeting was April 29, 2024, with 51,850,667 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors - Three Class III directors were elected to serve until the 2027 Annual Meeting.
- Vickie Capps: 48,034,233 votes For; 98,744 votes Withheld.
- Jay Lichter, Ph.D.: 46,352,481 votes For; 1,698,166 votes Withheld.
- Jake Simson, Ph.D.: 41,538,424 votes For; 6,589,319 votes Withheld.
- Proposal 2: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Results: 49,801,743 votes For; 1,682 votes Against; 1,328 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verification of the specific term length for the newly elected Class III directors (until 2027).
- Confirmation of the high level of support for the ratification of Ernst & Young LLP.
- Review of the significant number of votes withheld for director Jake Simson, Ph.D. (6,589,319 votes) compared to the other nominees.
- Confirmation that the company remains an emerging growth company as indicated by the checkmark in the filing.